KDNY | Chinook Therapeutics, Inc. | [NASD]
Index- P/E- EPS (ttm)-3.19 Insider Own1.80% Shs Outstand70.70M Perf Week9.63%
Market Cap1.50B Forward P/E- EPS next Y-3.45 Insider Trans-42.99% Shs Float62.26M Perf Month21.19%
Income-216.40M PEG- EPS next Q-0.82 Inst Own98.20% Short Float / Ratio7.02% / 6.39 Perf Quarter11.14%
Sales5.30M P/S283.08 EPS this Y-29.30% Inst Trans5.20% Short Interest4.37M Perf Half Y21.74%
Book/sh5.83 P/B4.16 EPS next Y-6.80% ROA-37.50% Target Price36.00 Perf Year74.71%
Cash/sh5.66 P/C4.28 EPS next 5Y9.00% ROE-47.10% 52W Range13.84 - 27.44 Perf YTD-7.44%
Dividend- P/FCF- EPS past 5Y13.60% ROI-42.90% 52W High-11.63% Beta0.14
Dividend %- Quick Ratio7.00 Sales past 5Y-18.70% Gross Margin- 52W Low75.22% ATR1.19
Employees214 Current Ratio7.00 Sales Q/Q-33.30% Oper. Margin- RSI (14)64.44 Volatility4.95% 5.73%
OptionableYes Debt/Eq0.00 EPS Q/Q-56.70% Profit Margin- Rel Volume0.80 Prev Close23.31
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume683.52K Price24.25
Recom1.50 SMA2012.94% SMA5011.76% SMA2008.56% Volume555,191 Change4.03%
Date Action Analyst Rating Change Price Target Change
Mar-06-23Initiated Piper Sandler Overweight $41
Mar-01-23Initiated Guggenheim Buy $43
Dec-05-22Initiated Wells Fargo Overweight $30
Jun-28-22Initiated Stifel Buy $30
Jan-06-21Initiated Wedbush Outperform $28
Dec-10-20Initiated Cantor Fitzgerald Overweight $31
Nov-16-20Initiated H.C. Wainwright Buy $28
Nov-02-20Initiated Evercore ISI Outperform $32
Oct-20-20Upgrade Oppenheimer Perform → Outperform $25
May-16-23 08:00AM
May-09-23 04:00PM
May-05-23 04:05PM
Apr-27-23 04:00PM
08:56AM Loading…
Apr-23-23 08:56AM
Apr-13-23 08:00AM
Apr-11-23 04:00PM
Apr-07-23 04:00PM
Mar-28-23 04:00PM
Mar-23-23 08:00AM
Mar-07-23 04:00PM
Mar-03-23 04:00PM
Feb-28-23 08:00AM
04:00PM Loading…
Feb-27-23 04:00PM
Feb-15-23 08:00AM
Feb-07-23 04:05PM
Feb-06-23 04:05PM
Jan-03-23 04:00PM
Nov-22-22 04:05PM
Nov-10-22 04:00PM
Nov-04-22 10:00AM
Nov-03-22 10:00AM
Nov-02-22 04:00PM
Oct-14-22 08:00AM
Sep-01-22 04:05PM
Aug-12-22 06:17AM
Aug-08-22 04:00PM
Aug-04-22 04:05PM
04:05PM Loading…
Aug-02-22 04:05PM
Jul-05-22 04:05PM
Jun-28-22 06:14AM
May-29-22 08:26AM
May-24-22 09:57PM
May-20-22 10:25AM
May-19-22 02:05AM
May-12-22 04:20PM
May-03-22 01:26PM
May-02-22 10:25AM
Apr-25-22 04:05PM
Apr-12-22 08:00AM
Apr-05-22 04:05PM
Mar-21-22 08:15AM
Mar-17-22 04:00PM
Mar-08-22 04:05PM
Feb-22-22 08:15AM
Feb-18-22 08:15AM
Feb-09-22 04:05PM
Feb-07-22 07:38AM
Feb-04-22 04:05PM
Jan-04-22 08:15AM
Dec-14-21 08:15AM
Dec-07-21 06:59AM
Nov-30-21 08:00AM
Nov-22-21 08:18PM
Nov-17-21 04:05PM
Nov-15-21 04:05PM
Nov-09-21 08:36PM
Nov-08-21 04:01PM
Nov-04-21 01:05PM
Oct-15-21 04:05PM
Oct-06-21 10:02AM
Sep-20-21 08:15AM
Sep-02-21 04:05PM
Aug-25-21 11:38AM
Aug-12-21 04:05PM
Jul-12-21 04:05PM
Jul-07-21 04:05PM
Jul-06-21 05:21AM
Jun-09-21 08:15AM
Jun-08-21 08:15AM
May-25-21 04:05PM
May-13-21 04:05PM
May-12-21 04:05PM
May-04-21 04:15PM
Apr-15-21 08:15AM
Apr-08-21 04:30PM
Apr-07-21 04:05PM
Apr-05-21 08:15AM
Apr-01-21 04:15PM
Mar-30-21 04:26PM
Mar-16-21 08:15AM
Mar-02-21 04:15PM
Mar-01-21 08:15AM
Feb-23-21 08:15AM
Feb-17-21 04:15PM
Feb-02-21 08:15AM
Jan-07-21 03:01AM
Jan-04-21 08:15AM
Dec-08-20 08:15AM
Nov-30-20 04:15PM
Nov-18-20 04:15PM
Nov-10-20 08:15AM
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOBMEIER ERICPresident, CEOApr 24Option Exercise0.4225,00010,500326,138Apr 26 05:19 PM
DOBMEIER ERICPresident, CEOApr 24Sale21.5823,800513,528302,338Apr 26 05:19 PM
Jerel DavisDirectorApr 17Sale20.75295,8086,138,223443,713Apr 19 05:58 PM
Krishnan MaheshDirectorApr 04Sale23.0192421,2611,275Apr 04 09:14 PM
King Andrew JamesChief Scientific OfficerApr 03Option Exercise0.352,50087521,992Apr 05 04:43 PM
King Andrew JamesChief Scientific OfficerApr 03Sale23.345,000116,71816,992Apr 05 04:43 PM
Jerel DavisDirectorMar 01Sale22.75400,0009,100,000210,996Mar 03 04:13 PM
DOBMEIER ERICPresident, CEOFeb 10Sale23.758,097192,292301,138Feb 15 04:40 PM
Frohlich TomChief Operating OfficerFeb 10Sale23.753,70087,869150,777Feb 15 04:40 PM
King Andrew JamesChief Scientific OfficerFeb 10Sale23.752,39256,80619,492Feb 15 04:39 PM
BJERKHOLT ERICChief Financial OfficerFeb 10Sale23.7585720,35238,867Feb 15 04:41 PM
DOBMEIER ERICPresident, CEOJan 31Sale24.687,688189,757288,987Feb 01 08:32 PM
Frohlich TomChief Operating OfficerJan 31Sale24.684,566112,700147,674Feb 02 06:15 PM
King Andrew JamesChief Scientific OfficerJan 31Sale24.683,24480,06915,081Feb 02 06:13 PM
BJERKHOLT ERICChief Financial OfficerJan 31Sale24.682,89171,35737,289Feb 02 06:14 PM
DOBMEIER ERICPresident, CEOJan 30Option Exercise0.4225,00010,500296,676Feb 01 08:32 PM
DOBMEIER ERICPresident, CEOJan 30Sale24.5425,000613,612271,676Feb 01 08:32 PM
King Andrew JamesChief Scientific OfficerJan 03Option Exercise0.357,5002,62519,992Jan 04 07:44 PM
King Andrew JamesChief Scientific OfficerJan 03Sale25.8210,000258,1839,992Jan 04 07:44 PM
DOBMEIER ERICPresident, CEODec 14Option Exercise0.3530,00010,500271,676Dec 15 04:27 PM
Frohlich TomChief Operating OfficerDec 13Option Exercise0.4210,0004,200153,907Dec 15 04:28 PM
Frohlich TomChief Operating OfficerDec 13Sale25.0010,000250,005143,907Dec 15 04:28 PM
DOBMEIER ERICPresident, CEODec 01Option Exercise0.4260,00025,200271,676Dec 02 04:26 PM
DOBMEIER ERICPresident, CEODec 01Sale22.3130,000669,351241,676Dec 02 04:26 PM
BJERKHOLT ERICChief Financial OfficerDec 01Sale22.295,770128,60232,847Dec 02 04:25 PM
Frohlich TomChief Operating OfficerNov 07Option Exercise0.4210,0004,200153,907Nov 09 04:21 PM
Frohlich TomChief Operating OfficerNov 07Sale22.1610,000221,642143,907Nov 09 04:21 PM
Frohlich TomChief Operating OfficerOct 06Sale19.697,360144,933143,907Oct 11 04:33 PM
King Andrew JamesChief Scientific OfficerOct 06Sale19.693,55770,04412,492Oct 11 04:32 PM
Thomas DolcaDirectorSep 02Buy21.2210,000212,19410,000Sep 06 04:35 PM
King Andrew JamesChief Scientific OfficerAug 04Option Exercise0.355,0001,75010,897Aug 05 05:09 PM
King Andrew JamesChief Scientific OfficerAug 04Sale20.005,000100,0005,897Aug 05 05:09 PM
King Andrew JamesChief Scientific OfficerJul 11Option Exercise0.355,0001,75010,897Jul 13 04:11 PM
King Andrew JamesChief Scientific OfficerJul 11Sale18.095,00090,4685,897Jul 13 04:11 PM